Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints News – Biotech and pharma business news, with a focus …
Endpoints News provides up-to-date biotech, drug, pharma, and health news for business and professional readers.
News – Endpoints News
reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email
Big dreams dominate among next-gen biotech players
Sep 22, 2024 · Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or …
Women in Biopharma 2023
Award Presentation . Though women account for roughly half of all employees in the biopharma industry — and growing, according to a recent BIO report — they occupy few executive and C-suite roles, especially in R&D.
Agenda: Endpoints at #JPM24
Catalent CEO Alessandro Maselli will be back at the big JPM healthcare confab to talk with Endpoints News founder John Carroll about their top predictions of what’s coming up for the biotech industry in 2024.
The Endpoints 11 2023 winners: Biotech’s most exciting startups
Sep 21, 2023 · The Endpoints 11: The biotech startups making the biggest bets with the most exciting science in 2023
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
Endpoints is on the ground at ESMO this year and the lineup will be one to watch — what drugs in the cancer pipeline show promise? Which ones won’t make it past the goal line? Join us as we break down the highlights and readouts with our expert roundtable moderated by Endpoints journalists and more. Tune in online as our team reports from …
Endpoints at #BIO23: The dawn of a new biotech era
The dawn of a new biotech era. The biotech industry’s annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma.
After years of hype, the first AI-designed drugs fall short in the clinic
Oct 19, 2023 · Recursion stands apart as the only one of the three to maintain a valuation above $1 billion today. (Exscientia is worth about $650 million, while BenevolentAI is ...